Opinion
Video
Author(s):
Panelists discuss how future trials in metastatic castration-resistant prostate cancer (mCRPC) should focus on developing reliable biomarker-driven treatment selection strategies to optimize sequencing decisions and identify which patients will benefit most from specific therapies or combinations, particularly as the treatment landscape becomes increasingly complex.
Video content above is prompted by the following:
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.